Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...

Tempus AI’s fair value estimate has been trimmed slightly from US$87.92 to US$86.71 per share, a small adjustment that still matters if you are tracking valuation closely. That shift sits alongside ...

Austria and Germany have joined France in calling for the resignation of United Nations Special Rapporteur for the "Occupied Palestinian Territories" Francesca Albanese following her recent remarks ...

AI-Powered Investing in 2026: How Algorithms Will Shape Your Portfolio AI is becoming a standard investing tool, as it helps cut through the noise, personalize portfolios and manage risk.